Remus Pharmaceuticals Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Operating Revenue	7,480	6,204	2,129	450.27	247.17	184.18
Other Revenue	-	-	-	1.05	-	3.9
Revenue	7,480	6,204	2,129	451.32	247.17	188.08
Revenue Growth (YoY)	63.84%	191.33%	371.81%	82.59%	31.42%	51.44%
Cost of Revenue	6,510	5,330	1,635	214.69	122.81	115.04
Gross Profit	969.1	873.9	494.6	236.63	124.36	73.04
Selling, General & Admin	134.4	131.1	73.2	54.7	34.24	29.95
Other Operating Expenses	320.4	285.9	131.8	70.45	46.32	29.71
Operating Expenses	479.3	435.7	216.2	129.92	82.1	61.41
Operating Income	489.8	438.2	278.4	106.71	42.26	11.63
Interest Expense	-12.9	-14.6	-5	-2.04	-0.78	-0.29
Interest & Investment Income	29	29	22.5	3.48	2.45	0.69
Currency Exchange Gain (Loss)	9.8	9.8	5.6	6.24	2.22	0.53
Other Non Operating Income (Expenses)	14.7	8.9	0.1	-0.26	-0.09	-0.06
EBT Excluding Unusual Items	530.4	471.3	301.6	114.14	46.06	12.5
Gain (Loss) on Sale of Investments	-	-	-	-	0.08	1.08
Gain (Loss) on Sale of Assets	2.1	2.1	-	-	-	-
Pretax Income	532.5	473.4	301.6	114.14	46.13	13.58
Income Tax Expense	110.9	89.2	58.9	29.11	11.79	3.32
Earnings From Continuing Operations	421.6	384.2	242.7	85.03	34.34	10.26
Minority Interest in Earnings	-86.5	-93.5	-37.5	-	-	-
Net Income	335.1	290.7	205.2	85.03	34.34	10.26
Net Income to Common	335.1	290.7	205.2	85.03	34.34	10.26
Net Income Growth	12.07%	41.67%	141.33%	147.60%	234.77%	26.39%
Shares Outstanding (Basic)	12	12	11	8	8	8
Shares Outstanding (Diluted)	12	12	11	8	8	8
Shares Change (YoY)	3.88%	4.28%	38.35%	2.10%	-	-
EPS (Basic)	27.37	24.67	18.16	10.41	4.29	1.28
EPS (Diluted)	27.37	24.67	18.16	10.41	4.29	1.28
EPS Growth	7.89%	35.85%	74.43%	142.51%	234.77%	26.39%
Free Cash Flow	22.4	30	-19.4	25.81	49.67	27.72
Free Cash Flow Per Share	1.83	2.55	-1.72	3.16	6.21	3.46
Dividend Per Share	0.750	0.750	0.750	0.250	-	-
Dividend Growth	-	-	200.00%	-	-	-
Gross Margin	12.96%	14.09%	23.23%	52.43%	50.31%	38.83%
Operating Margin	6.55%	7.06%	13.07%	23.64%	17.10%	6.18%
Profit Margin	4.48%	4.69%	9.64%	18.84%	13.89%	5.45%
Free Cash Flow Margin	0.30%	0.48%	-0.91%	5.72%	20.09%	14.74%
EBITDA	507.5	450.1	287.2	111.36	43.81	13.38
EBITDA Margin	6.78%	7.26%	13.49%	24.67%	17.72%	7.11%
D&A For EBITDA	17.7	11.9	8.8	4.64	1.55	1.75
EBIT	489.8	438.2	278.4	106.71	42.26	11.63
EBIT Margin	6.55%	7.06%	13.07%	23.64%	17.10%	6.18%
Effective Tax Rate	20.83%	18.84%	19.53%	25.50%	25.56%	24.47%
Revenue as Reported	7,535	6,253	2,158	466.05	254.37	192.25

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.